Elanco Animal Health posts Q3 2026 profit and lifts full‑year 2026 revenue and EPS outlook
Elanco Animal Health reported third‑quarter 2026 revenue of $1.265 billion, up 11% year‑over‑year, and adjusted earnings of $0.27 per share. The company raised its full‑year 2026 revenue guidance to $5.155 billion‑$5.18 billion and adjusted EPS guidance to $1.17‑$1.20. Net leverage improved to 2.9 x adjusted EBITDA, and the firm highlighted strong growth from Zenrelia and Credelio Quattro.
Why it matters
The higher revenue and EPS guidance expands the market’s expectations for Elanco’s 2026 earnings, potentially supporting a re‑rating of the stock’s valuation (the company said the guidance reflects accelerated cash‑flow generation). The improved net‑leverage ratio gives the company more flexibility for capital allocation, which may affect dividend or buy‑back decisions.
Key facts
- 1Q3 2026 revenue was $1.265 billion, an 11% year‑over‑year increase. prnewswire.com
- 2Adjusted EPS for the quarter was $0.27. prnewswire.com
- 3Full‑year 2026 revenue guidance was raised to $5.155 billion‑$5.18 billion, or about 8% organic constant‑currency growth. prnewswire.com
- 4Full‑year 2026 adjusted EPS guidance was raised to $1.17‑$1.20, a 26% year‑over‑year increase at the midpoint. prnewswire.com
- 5Net leverage ratio reached 2.9 x adjusted EBITDA. prnewswire.com
- 6Adjusted EBITDA for the quarter was $243 million, with a margin of 19.5%. sec.gov
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.